Detection of CBFβ/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Bone Marrow Transplantation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bmt.1701056
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection and quantitation of the CBFβ/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML

  1997cited by this paper
• Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.

  1996cited by this paper

• How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring

  2021cites this paper
• Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse

  2021cites this paper
• Molecular methods for measurable residual disease in acute myeloid leukemia: where are we and where are we going?

  2021cites this paper
• How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)

  2020cites this paper
• Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy

  2020cites this paper
• How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation.

  2020cites this paper
• Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia

  2019cites this paper
• Strategies for minimal residual disease detection: current perspectives

  2019cites this paper
• Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

  2019cites this paper
• Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post‐transplantation minimal residual disease (MRD) monitoring and MRD‐directed intervention

  2017cites this paper
• Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making

  2017cites this paper
• Relapse of Hematologic Malignancy After Allogeneic Hematopoietic Transplantation

  2016cites this paper
• Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT

  2016cites this paper
• Akute myeloische Leukämie

  2015cites this paper
• A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1, and FLT3-ITD mutations after allogeneic stem cell transplantation

  2014cites this paper
• Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders.

  2014cites this paper
• Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation

  2013cites this paper
• Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies.

  2012cites this paper
• Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia.

  2012cites this paper
• The Detection and Significance of Minimal Residual Disease

  2012cites this paper
• Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid Leukemia

  2011cites this paper
• NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods,

  2010cites this paper
• Minimal Residual Disease

  2010cites this paper
• Minimal residual disease diagnostics in myeloid malignancies in the post transplant period

  2008cites this paper
• Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification.

  2008cites this paper
• Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment.

  2007cites this paper
• Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.

  2007cites this paper
• Analysen des hämatopoetischen Chimärismus in Zellsubpopulationen mit Hilfe der fluoreszensmarkierten STR-PCR bei Kindern mit akuten Leukämien. Erarbeitung prognostischer Parameter zur Rezidivfrüherkennung

  2007cites this paper
• The detection and significance of minimal residual disease in acute and chronic leukemia.

  2006cites this paper
• Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation

  2005cites this paper
• Detection of Minimal Residual Disease in Acute Myelogenous Leukemia

  2004cites this paper
• A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.

  2004cites this paper
• Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme

  2004cites this paper
• Therapy of Acute Myeloid Leukemia in Adults

  2003cites this paper
• Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT–PCR useful clinically?

  2003cites this paper
• The Methodology and Significance of Minimal Residual Disease Detection after Allogeneic Stem Cell Transplantation

  2003cites this paper
• Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.

  2003cites this paper
• Monitoring AML1-ETO and CBFΒ-MYH11 transcripts in acute myeloid leukemia

  2003cites this paper
• Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms

  2003cites this paper
• Minimal Residual Disease in Allogeneic Recipients

  2003cites this paper
• Akute myeloische Leukämien

  2003cites this paper
• Minimal residual disease in acute myeloid leukaemia.

  2002cites this paper
• Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse after autologous bone marrow transplantation.

  2002cites this paper
• Minimal Residual Disease in Acute Myeloid Leukemia

  2002cites this paper
• Two more inv(16) acute myeloid leukemia cases with infrequent CBFbeta-MYH11 fusion transcript: clinical and molecular findings.

  2002cites this paper
• Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)‐positive acute myeloblastic leukemia by real‐time RT‐PCR

  2001cites this paper
• A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase

  2001cites this paper
• Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation

  2001cites this paper
• Prospective Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia with Inversion(16) by CBFβ/MYH11 RT-PCR: Implications for a Monitoring Schedule and for Treatment Decisions

  2001cites this paper
• Detection of minimal residual disease.

  2001cites this paper
• Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia

  2001cites this paper
• Avaliação de doença residual mínima pós-transplante de medula óssea

  2000cites this paper
• 自家骨髄移植術を用いて治療したinv (16) (p13;q22) 急性骨髄性白血病 (FABM4E) の1例

  2000cites this paper
• GVL Effects in Human Marrow Stem-Cell Transplants

  2000cites this paper
• The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation

  2000cites this paper
• Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells

  1999cites this paper
• Minimal residual disease.

  1999cites this paper
• 小児白血病における微少残存腫瘍 (MRD) の臨床的意義

  1999cites this paper
• Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease

  1999cites this paper